Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Launched by SHANGHAI PHARMACEUTICALS HOLDING CO., LTD · Jan 9, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment called LT3001 for people who have experienced an acute ischemic stroke, which is a type of stroke caused by a blockage that prevents blood from reaching the brain. The study aims to see how safe and effective LT3001 is when given to patients within 24 hours of having a stroke. It is currently looking for participants aged between 18 and 80 years who have a certain level of neurological impairment, as measured by a specific scoring system.

To be eligible, participants need to have had a stroke that meets certain criteria, and they should not have received specific treatments for their stroke before joining the study. Individuals who are pregnant, breastfeeding, or have certain medical conditions may not be able to participate. If eligible, participants will receive the investigational drug and be monitored closely during the study. This trial is an important step in finding new ways to treat strokes and potentially improve recovery for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects aged between 18 and 80 years at screening;
• • 2. Clinical diagnosis of acute ischemic stroke that causes evaluable neurological impairment; 3.4 points ≤ NIHSS score ≤ 25 points at randomization;
• • 4.Subjects who are able to receive the investigational drug within 24 hours after the onset of stroke; 5.Female subjects of childbearing potential or male subjects whose sexual partner are women of childbearing potential have no pregnancy plan and voluntarily take effective contraceptive measures during the study period and for 3 months after the last dose; 6.All subjects sign the informed consent form by themselves or their guardians after receiving complete study information.
• Exclusion Criteria:
• • 1. Subjects have received or plan to receive endovascular treatment and/or intravenous thrombolytic therapy recommended by Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018 during this onset period;
• • 2. Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points;
• • 3. Neurological signs have improved rapidly and spontaneously at screening;
• • 4. Subjects who have used or are using protocol-prohibited medications after the onset;
• • 5. Subjects with pre-stroke disability;
• • 6. Subjects with intracranial hemorrhagic diseases, tumor in brain parenchyma, arteriovenous malformation, aortic arch dissection, other central nervous system lesions that may increase the risk of hemorrhage, or imaging evidence for arterial aneurysm requiring treatment;
• • 7. Massive infarction on imaging;
• • 8. Patients who are unable to cooperate due to epileptic seizure at the onset of stroke or other concomitant mental disorders or are unwilling to cooperate;
• • 9. Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg after active antihypertensive therapy;
• • 10. Acute hemorrhage tendency;
• • 11. Blood glucose level \< 50 mg/dL or \> 400 mg/dL;
• • 12. Active visceral hemorrhage;
• • 13. Lactating or pregnant subjects, or women of childbearing potential with positive pregnancy test results;
• • 14. International normalized ratio \> 1.7 or prothrombin time \> 15 s;
• • 15. Subjects with a history of serious hypersensitivity;
• • 16. Subjects who experienced AIS, ICH, acute myocardial infarction or serious head trauma before screening;
• • 17. Subjects who underwent any major surgery before screening;
• • 18. Subjects with a history of active digestive ulcer before screening;
• • 19. Subjects who experienced hemorrhagic disease before screening;
• • 20. Subjects who underwent arterial puncture at the site not easy for hemostasis by compression before screening;
• • 21. Serious hepatic impairment or serious renal insufficiency;
• • 22. Subjects who have participated in another investigational study and used investigational product before screening;
• • 23. Other conditions unsuitable for participation in this study determined by the Investigator.